Physician profile
Stephen H Little
NPI 1659412336
$143,893.21
in general payments reported to CMS, 2019-2025
21 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $15K · 2021: $914 · 2022: $2,409 · 2023: $3,039 · 2024: $3,470 · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $67K · Travel and Lodging: $30K · Food and Beverage: $8,064 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,440 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $67,012.50 |
| Travel and Lodging | $30,114.52 |
| Food and Beverage | $8,064.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,440.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $121,370.97 | 2019-2025 | Mitraclip, Triclip, Navitor |
| Siemens Medical Solutions USA, INC. | $7,122.88 | 2023-2025 | Acuson Sc2000 Diagnostic Ultrasound System, Acuson Origin Diagnostic Ultrasound System, Acuson Sequoia Diagnostic Ultrasound System |
| Medtronic, INC. | $6,852.17 | 2021-2025 | Corevalve Evolut R, Apollotm, Onyx Frontier |
| Medtronic Vascular, INC. | $4,454.21 | 2019-2020 | |
| Edwards Lifesciences Corporation | $3,142.97 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $160.65 | 2019-2023 | Bodyguardian |
| Ge Healthcare | $144.76 | 2019-2022 | |
| Baxter Healthcare | $121.64 | 2019 | |
| Livanova USA, INC. | $119.35 | 2020 | |
| Jenavalve Technology, INC. | $103.42 | 2023-2025 | Jenavalve Pericardial Tavr System |
| Pfizer INC. | $57.90 | 2019-2023 | |
| Heartflow, INC. | $48.74 | 2023 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $36.51 | 2025 | Camzyos |
| Bridgebio Pharma, INC. | $30.67 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.29 | 2025 | Lifevest |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bracco Diagnostics INC. | $20.19 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.61 | 2024 | Xarelto |
| Tactile Systems Technology INC | $19.36 | 2024 | Flexitouch Plus, Entre Plus |
| Astellas Pharma US INC | $14.68 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.56 | 2019 | |
| Amgen INC. | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.